---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-040697"
form_type: "8-K"
ticker: null
cik: "0001827506"
company_name: "Tourmaline Bio, Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:43:36.910444+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Talaris discontinues kidney transplant trials, cuts 1/3 of staff, explores strategic alternatives

## Summary
- Discontinues FREEDOM-1 and FREEDOM-2 kidney transplant trials due to slow enrollment; continues FREEDOM-3 scleroderma trial.
- Workforce reduced by ~1/3; remaining employees focus on cell therapy CMC and FREEDOM-3 trial.
- Expects ~$2.9M in restructuring costs in Q1-Q2 2023; cash position ~$181.3M as of Dec 31, 2022.
- Initiates comprehensive strategic review including possible business combinations or divestiture of cell therapy CMC.
- No timetable set for strategic review; suspends further program guidance.

## SEC filing metadata
- accession: 0001193125-23-040697
- form_type: 8-K
- cik: 0001827506
- company_name: Tourmaline Bio, Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/0001193125-23-040697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/d357370d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-040697
- JSON: https://secwatch.observer/filing/0001193125-23-040697.json
- Plain text: https://secwatch.observer/filing/0001193125-23-040697.txt

## Key facts
- Restructurings & Charges
  Tourmaline Bio, Inc. announced a restructuring with charges of approximately $2.9 million for retention, severance and other employee termination-related costs affecting workforce reduction by approximately one-third (reducing the Company's workforce by approximately one-third).
  - Type: restructuring
  - Charge: approximately $2.9 million for retention, severance and other employee termination-related costs
  - Affected area: workforce reduction by approximately one-third
  - Headcount: reducing the Company's workforce by approximately one-third
  source text: clinical development programs and further prioritization of the Company’s resources as it assesses strategic alternatives. The Company estimates that it will incur approximately $2.9 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023. The estimate of costs that the Company expects to incur and the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/0001193125-23-040697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.